Abstract
Immunological Signatures Associated With Ocrelizumab Treatment in Early RRMS: 12-Month Interim Analysis From the Ocrelizumab Phase IIIb (ENSEMBLE; NCT03085810) Immunological Substudy (S16.003)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have